House Bill 4005 requires drug manufacturers to compile a report on a prescription drug if the price was $100 or more for a 1-month supply (or course of treatment lasting less than 1 month) and if the net price increased by 10% or more.
Earlier this week, Oregon Governor Kate Brown, D, signed a bill that looks to provide more transparency around drug pricing.
House Bill 4005 requires drug manufacturers to compile a report on a prescription drug if the price was $100 or more for a 1-month supply (or course of treatment lasting less than 1 month) and if the net price increased by 10% or more.
For drugs that fit into these criteria, manufacturers would need to provide information to explain the factors that contributed to the price increase, such as:
Under the law, pharmaceutical companies must provide these reports by July 2019.
In addition, the bill creates a drug pricing task force and mandates that Oregon’s Department of Consumer and Business Services post a list of high drug price increases. Furthermore, the bill also requires that insurers show how these drug prices affect premiums.
“Every Oregonian should be able to access the medications and treatments that allow them to live healthy, productive lives. This bill brings greater transparency around drug pricing, an important step towards making life-saving and essential drugs more affordable,” said Governor Brown in a statement.
As soon as the bill was signed, the pharmaceutical industry responded.
“[The law] will have a chilling effect on an innovative industry and do nothing to empower patients or lower their prescription drug costs,” said Biotechnology Innovation Organization’s CEO, Jim Greenwood, in a statement.
According to the National Academy for State Health Policy, state legislatures are currently considering 78 bills to regulate pharmacy benefit managers (PBMs), 48 that focus on drug pricing transparency, 11 that address so-called "price-gouging" and more on a variety of other topics, including the importation of drugs.
The proposed bills have received pushback from the industry, with pharmaceutical companies sending lobbyists to state governments around the country, according to Kaiser Health News.
Other states, including Louisiana, Nevada, Maryland, North Carolina, and Vermont have also passed measures that aim to increase transparency in drug pricing.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.